Annual EBITDA
-$46.53 M
+$1.09 M+2.28%
30 September 2023
Summary:
Anavex Life Sciences annual earnings before interest, taxes, depreciation & amortization is currently -$46.53 million, with the most recent change of +$1.09 million (+2.28%) on 30 September 2023. During the last 3 years, it has fallen by -$8.89 million (-23.63%). AVXL annual EBITDA is now -320824.14% below its all-time high of -$14.50 thousand, reached on 30 September 2004.AVXL EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
-$12.28 M
-$1.84 M-17.62%
30 June 2024
Summary:
Anavex Life Sciences quarterly earnings before interest, taxes, depreciation & amortization is currently -$12.28 million, with the most recent change of -$1.84 million (-17.62%) on 30 June 2024. Over the past year, it has dropped by -$2.07 million (-20.28%). AVXL quarterly EBITDA is now -3491.60% below its all-time high of $362.10 thousand, reached on 31 December 2013.AVXL Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
-$44.23 M
-$1.04 M-2.41%
30 June 2024
Summary:
Anavex Life Sciences TTM earnings before interest, taxes, depreciation & amortization is currently -$44.23 million, with the most recent change of -$1.04 million (-2.41%) on 30 June 2024. Over the past year, it has increased by +$4.68 million (+9.56%). AVXL TTM EBITDA is now -1078558.54% below its all-time high of -$4100.00, reached on 31 December 2004.AVXL TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
AVXL EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | -20.3% | +9.6% |
| 3 y3 years | -23.6% | -54.6% | -17.5% |
| 5 y5 years | -61.5% | -95.8% | -53.5% |
AVXL EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -23.6% | +2.3% | -54.6% | +20.0% | -17.5% | +17.8% |
| 5 y | 5 years | -61.5% | +2.3% | -95.8% | +20.0% | -54.3% | +17.8% |
| alltime | all time | <-9999.0% | +2.3% | -3491.6% | +20.0% | <-9999.0% | +17.8% |
Anavex Life Sciences EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2024 | - | -$12.28 M(+17.6%) | -$44.23 M(+2.4%) |
| Mar 2024 | - | -$10.44 M(-7.5%) | -$43.18 M(-3.7%) |
| Dec 2023 | - | -$11.29 M(+10.6%) | -$44.84 M(-8.3%) |
| Sept 2023 | -$46.53 M(-2.3%) | -$10.21 M(-9.2%) | -$48.90 M(-7.3%) |
| June 2023 | - | -$11.24 M(-7.1%) | -$52.77 M(-1.9%) |
| Mar 2023 | - | -$12.09 M(-21.3%) | -$53.81 M(+1.1%) |
| Dec 2022 | - | -$15.36 M(+9.1%) | -$53.24 M(+7.3%) |
| Sept 2022 | -$47.62 M(+26.5%) | -$14.08 M(+14.7%) | -$49.60 M(+14.1%) |
| June 2022 | - | -$12.28 M(+6.6%) | -$43.47 M(+2.2%) |
| Mar 2022 | - | -$11.52 M(-1.7%) | -$42.54 M(+6.4%) |
| Dec 2021 | - | -$11.72 M(+47.5%) | -$39.97 M(+6.2%) |
| Sept 2021 | -$37.64 M(+21.7%) | -$7.95 M(-30.0%) | -$37.64 M(+1.2%) |
| June 2021 | - | -$11.36 M(+27.0%) | -$37.20 M(+9.6%) |
| Mar 2021 | - | -$8.94 M(-4.8%) | -$33.95 M(+3.8%) |
| Dec 2020 | - | -$9.40 M(+25.2%) | -$32.71 M(+5.7%) |
| Sept 2020 | -$30.94 M(+7.4%) | -$7.51 M(-7.4%) | -$30.94 M(+4.2%) |
| June 2020 | - | -$8.11 M(+5.3%) | -$29.70 M(+3.6%) |
| Mar 2020 | - | -$7.70 M(+0.9%) | -$28.67 M(-1.3%) |
| Dec 2019 | - | -$7.63 M(+21.6%) | -$29.03 M(+0.8%) |
| Sept 2019 | -$28.81 M(+50.2%) | -$6.27 M(-11.3%) | -$28.81 M(+1.6%) |
| June 2019 | - | -$7.07 M(-12.3%) | -$28.35 M(+9.8%) |
| Mar 2019 | - | -$8.07 M(+9.0%) | -$25.82 M(+14.8%) |
| Dec 2018 | - | -$7.40 M(+27.3%) | -$22.49 M(+17.2%) |
| Sept 2018 | -$19.18 M(+23.5%) | -$5.81 M(+28.0%) | -$19.18 M(+3.4%) |
| June 2018 | - | -$4.54 M(-4.0%) | -$18.55 M(+5.1%) |
| Mar 2018 | - | -$4.73 M(+15.7%) | -$17.64 M(+6.9%) |
| Dec 2017 | - | -$4.09 M(-21.0%) | -$16.50 M(+6.2%) |
| Sept 2017 | -$15.54 M(+0.6%) | -$5.18 M(+42.4%) | -$15.54 M(-8.1%) |
| June 2017 | - | -$3.64 M(+1.2%) | -$16.92 M(+9.0%) |
| Mar 2017 | - | -$3.59 M(+14.6%) | -$15.53 M(+10.2%) |
| Dec 2016 | - | -$3.13 M(-52.2%) | -$14.09 M(-5.3%) |
| Sept 2016 | -$15.45 M(+28.3%) | -$6.55 M(+191.9%) | -$14.88 M(-13.6%) |
| June 2016 | - | -$2.25 M(+4.3%) | -$17.21 M(+4.4%) |
| Mar 2016 | - | -$2.15 M(-45.1%) | -$16.48 M(+8.5%) |
| Dec 2015 | - | -$3.92 M(-55.9%) | -$15.19 M(+26.8%) |
| Sept 2015 | -$12.04 M(+305.5%) | -$8.89 M(+488.0%) | -$11.97 M(+172.4%) |
| June 2015 | - | -$1.51 M(+76.3%) | -$4.40 M(+13.2%) |
| Mar 2015 | - | -$858.10 K(+20.9%) | -$3.88 M(-3.8%) |
| Dec 2014 | - | -$709.50 K(-46.1%) | -$4.04 M(+36.1%) |
| Sept 2014 | -$2.97 M | -$1.32 M(+31.6%) | -$2.97 M(-35.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2014 | - | -$1.00 M(-1.3%) | -$4.63 M(+22.9%) |
| Mar 2014 | - | -$1.01 M(-379.9%) | -$3.77 M(+32.5%) |
| Dec 2013 | - | $362.10 K(-112.2%) | -$2.84 M(-22.1%) |
| Sept 2013 | -$3.65 M(-54.8%) | -$2.98 M(+2072.7%) | -$3.65 M(+172.6%) |
| June 2013 | - | -$137.10 K(+53.4%) | -$1.34 M(-76.5%) |
| Mar 2013 | - | -$89.40 K(-79.8%) | -$5.69 M(-11.3%) |
| Dec 2012 | - | -$442.80 K(-33.8%) | -$6.42 M(-20.5%) |
| Sept 2012 | -$8.06 M(+30.7%) | -$669.10 K(-85.1%) | -$8.07 M(+4.7%) |
| June 2012 | - | -$4.49 M(+450.7%) | -$7.71 M(+60.9%) |
| Mar 2012 | - | -$815.10 K(-61.1%) | -$4.79 M(-19.4%) |
| Dec 2011 | - | -$2.09 M(+579.5%) | -$5.94 M(+13.9%) |
| Sept 2011 | -$6.17 M(+9.3%) | -$308.10 K(-80.4%) | -$5.21 M(-24.1%) |
| June 2011 | - | -$1.57 M(-20.1%) | -$6.87 M(+4.1%) |
| Mar 2011 | - | -$1.97 M(+43.9%) | -$6.60 M(+4.5%) |
| Dec 2010 | - | -$1.37 M(-30.4%) | -$6.31 M(+17.1%) |
| Sept 2010 | -$5.65 M(+19.3%) | -$1.96 M(+50.7%) | -$5.39 M(+3.1%) |
| June 2010 | - | -$1.30 M(-22.4%) | -$5.23 M(+0.9%) |
| Mar 2010 | - | -$1.68 M(+279.2%) | -$5.18 M(+21.3%) |
| Dec 2009 | - | -$442.90 K(-75.4%) | -$4.27 M(-9.8%) |
| Sept 2009 | -$4.73 M(-10.2%) | -$1.80 M(+43.3%) | -$4.73 M(-15.8%) |
| June 2009 | - | -$1.26 M(+63.2%) | -$5.62 M(+5.0%) |
| Mar 2009 | - | -$769.90 K(-15.0%) | -$5.36 M(+1.9%) |
| Dec 2008 | - | -$905.80 K(-66.3%) | -$5.26 M(-1.5%) |
| Sept 2008 | -$5.27 M(+234.0%) | -$2.69 M(+171.7%) | -$5.34 M(+40.9%) |
| June 2008 | - | -$990.20 K(+47.4%) | -$3.79 M(+24.0%) |
| Mar 2008 | - | -$671.70 K(-32.0%) | -$3.06 M(+19.7%) |
| Dec 2007 | - | -$987.50 K(-13.4%) | -$2.55 M(+61.8%) |
| Sept 2007 | -$1.58 M(+6063.7%) | -$1.14 M(+346.3%) | -$1.58 M(+256.5%) |
| June 2007 | - | -$255.60 K(+51.4%) | -$442.50 K(+129.8%) |
| Mar 2007 | - | -$168.80 K(+1272.4%) | -$192.60 K(+575.8%) |
| Dec 2006 | - | -$12.30 K(+112.1%) | -$28.50 K(+11.3%) |
| Sept 2006 | -$25.60 K(-72.1%) | -$5800.00(+1.8%) | -$25.60 K(-58.6%) |
| June 2006 | - | -$5700.00(+21.3%) | -$61.80 K(-39.3%) |
| Mar 2006 | - | -$4700.00(-50.0%) | -$101.80 K(-28.7%) |
| Dec 2005 | - | -$9400.00(-77.6%) | -$142.80 K(+3.9%) |
| Sept 2005 | -$91.70 K(+532.4%) | -$42.00 K(-8.1%) | -$137.50 K(+44.0%) |
| June 2005 | - | -$45.70 K(0.0%) | -$95.50 K(+91.8%) |
| Mar 2005 | - | -$45.70 K(+1014.6%) | -$49.80 K(+1114.6%) |
| Dec 2004 | - | -$4100.00 | -$4100.00 |
| Sept 2004 | -$14.50 K | - | - |
FAQ
- What is Anavex Life Sciences annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for Anavex Life Sciences?
- What is Anavex Life Sciences quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for Anavex Life Sciences?
- What is Anavex Life Sciences quarterly EBITDA year-on-year change?
- What is Anavex Life Sciences TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for Anavex Life Sciences?
- What is Anavex Life Sciences TTM EBITDA year-on-year change?
What is Anavex Life Sciences annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of AVXL is -$46.53 M
What is the all time high annual EBITDA for Anavex Life Sciences?
Anavex Life Sciences all-time high annual earnings before interest, taxes, depreciation & amortization is -$14.50 K
What is Anavex Life Sciences quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of AVXL is -$12.28 M
What is the all time high quarterly EBITDA for Anavex Life Sciences?
Anavex Life Sciences all-time high quarterly earnings before interest, taxes, depreciation & amortization is $362.10 K
What is Anavex Life Sciences quarterly EBITDA year-on-year change?
Over the past year, AVXL quarterly earnings before interest, taxes, depreciation & amortization has changed by -$2.07 M (-20.28%)
What is Anavex Life Sciences TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of AVXL is -$44.23 M
What is the all time high TTM EBITDA for Anavex Life Sciences?
Anavex Life Sciences all-time high TTM earnings before interest, taxes, depreciation & amortization is -$4100.00
What is Anavex Life Sciences TTM EBITDA year-on-year change?
Over the past year, AVXL TTM earnings before interest, taxes, depreciation & amortization has changed by +$4.68 M (+9.56%)